PEARCE IP
Our Capabilities
We prosecute patent and trade mark applications around the world, coordinate and execute local and multi-jurisdictional IP litigation strategies and provide IP/legal support for regional and global business development activities and licensing deals.
IP EXPERTS
Our Leaders
Naomi Pearce
Principal Lawyer, Patent Attorney, Trade Mark Attorney
Jacinta Flattery O’Brien PhD
Special Counsel, Patent Attorney
Jennifer Enmon PhD, JD
Special Counsel, Patent Attorney, Trade Mark Attorney
Grant Shoebridge PhD
Special Counsel, Patent Attorney
Kadri Elcoat
Special Counsel, Lawyer
Kate Legge
Special Counsel, Lawyer
PEARCE IP BLOG
Read our latest updates & insights
Pearce IP BioBlast®: w/e 26 February 2021
23 Feb 2021 | In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab...
Pearce IP BioBlast®: w/e 19 February 2021
13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution...
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
infliximab | Remicade® | Johnson & Johnson
natalizumab | Tysabri® | Biogen/Elan
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | Merck
ranibizumab | Lucentis® | Genentech
rituximab | Rituxan®/MabThera® | Genentech/Biogen
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
OUR VISION
At Pearce IP our lawyers and attorneys have “raised the bar” for patent services. We work with life sciences clients to create and implement IP strategies with impact. From conception to post commercialisation our patent professionals provide work that is on point and on time. We help change the world, one patent at a time.